Opportunistic PK/PD Trial in Critically Ill Children (OPTIC)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age0-20
SponsorDuke University

About this trial

OPTIC is a prospective, open-label, non-randomized study of multiple medications administered to approximately 2000 children in the pediatric cardiac intensive care unit (PCICU) per routine clinical car by their treating provider. The purpose of this study is to characterize the PK of drugs routinely administered to children per standard of care using opportunistic and scavenged samples. The prescribing of drugs to children will not be part of this protocol.

After the child/adult (\<21 years of age) is consented/enrolled, demographic and clinical data will be extracted from the EHR. Biospecimen information (including date and time of sample collection) will be collected.

Data analysis will be conducted on all participants with at least 2 evaluable samples. The protocol represents minimal risk to the children/adults who provide body fluid for this study, including potential loss of confidentiality (samples will be assigned a unique accession number) and risks associated with blood draws. Adverse Events (AEs)/Serious Adverse Events (SAEs) caused by the study specimen collections will be monitored and recorded in the Electronic Data Capture (EDC) system.

Eligibility criteria

Qualifiers

Participant is <21 years old on admission

Participant is admitted to the Pediatric Cardiac Intensive Care Unit

Parent/legal guardian/adult participant can understand the consent process and is willing to provide informed consent/assent

Participant is receiving one or more of the study drugs of interest at the time of enrollment

Disqualifiers

None

Trial design

Treatments tested in this trial

  • The OPTIC study is collecting PK data on children prescribed understudied drugs of interest per standard of care.

Treatment groups

2,000 Participants
are divided into 1 treatment group

Sponsors and collaborators

Duke University

Lead sponsor

Food and Drug Administration (FDA)

Collaborator